In patients with non-small cell lung cancer, certain comorbidities impact survival
the ONA take:
According to a new study published in the journal Lung, researchers have found that certain comorbidities in patients with non-small cell lung cancer (NSCLC) significantly negatively impact survival. For the study, researchers sought to investigate the negative prognostic factor of individual comorbidities in patients with primary lung cancer. They identified 10,378 patients who were diagnosed with NSCLC between 2009 and 2011. Results showed that patients with NSCLC and cardiovascular comorbidity have a 30% increased mortality rate (HR = 1.30; 95% CI: 1.13 - 1.49) compared with those without comorbidity. In addition, patients with diabetes (HR = 1.19; 95% CI: 1.02 - 1.39), cerebrovascular disorders (HR = 1.18; 95% CI: 1.05 - 1.33), and chronic obstructive pulmonary disease (COPD) (HR = 1.20; 95% CI: 1.10 - 1.39) have an approximately 20% increased mortality rate compared with those without comorbidity.
Primary lung cancer is one of the most frequently occurring types of cancer, and morbidity has been shown to negatively impact survival in patients with lung cancer. This study shows that comorbid cardiovascular disease, diabetes, cerebrovascular disorders, and COPD individually increase the death rate of patients by 20% to 30%.
A family member serves as a caregiver for a patient with cancer.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
- Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment
- Mobile Health Apps Becoming More Popular Among Patients and Clinicians
- Online Learning Modules Improve Exercise Counseling, But Not Participation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|